drugset / Trial / NCT06377111

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

NCT06377111

Phase 1 Active not recruiting 12 enrolled University Health Network, Toronto
NaSingle-groupOpen-labelTreatment

Summary

This study is open to patients with a type of cancer called melanoma. Patients can join the study if their tumor cannot be removed by surgery or has spread to other organs, and are planned to receive immunotherapy as treatment for their cancer. This study is looking at whether taking calcium pantothenate supplement (a type of Vitamin B5) can increase its levels in the blood and have an effect in the immune system, when its used in combination with the immunotherapy.

Timeline

Start
2024-06-24
Primary completion
2027-08
Completion
2027-08

Drugs

EvaluationDrugModalityDoseRoute
Background Ipilimumab Monoclonal antibody 3 mg/kg
Background Nivolumab Monoclonal antibody 3 mg/kg
Background Nivolumab Monoclonal antibody 6 mg/kg
Background Nivolumab Monoclonal antibody 240 mg
Background Nivolumab Monoclonal antibody 480 mg

Indications